PLUS THERAPEUTICS, INC. 8-K

What Happened
Plus Therapeutics, Inc. (PSTV) filed an 8-K reporting that on March 20, 2026 the Board unanimously appointed Ronald A. Andrews as a director to fill the vacancy created by the resignation of Dr. Robert Lenk. Mr. Andrews is designated an “independent director” under Nasdaq rules, was also named to the Nominating and Corporate Governance Committee, and is expected to stand for reelection at the company’s 2026 annual meeting of stockholders.

Key Details

• Appointment and resignation effective March 20, 2026: Ronald A. Andrews appointed; Robert Lenk resigned.
• Independence & committee role: Board determined Andrews meets Nasdaq independence standards; he was added to the Nominating & Corporate Governance Committee.
• Background: Andrews has 35+ years in diagnostics/molecular diagnostics and has held CEO and board roles at multiple companies (e.g., Oncocyte, Twin Strand Biosciences, Thermo Fisher/Life Technologies).
• Compensation & formalities: Andrews will receive standard non-employee director compensation per the company’s July 21, 2025 proxy and is expected to sign the company’s standard director indemnification agreement; no related-party transactions or special arrangements were disclosed. Dr. Lenk said his resignation was not due to any disagreement with the company.

Why It Matters
This is a governance update — a new independent director with extensive diagnostics industry experience replaces a departing board member. For investors, the change signals continuity in governance (an independent director added, committee coverage maintained) and brings additional industry expertise to the board, which could influence oversight of strategy in diagnostics-related programs. The filing contains no indication of operational disruptions or disagreements with management.